← All trials
NCT05869227
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 28, 2023
- Primary completion
- Apr 28, 2026
- Completion date
- Apr 28, 2029
- First posted
- May 22, 2023
- Last posted
- May 22, 2023
- Enrollment
- 166
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Sun Yat-Sen UniversityLead sponsor
- Southern Medical UniversityCollaborator
- Sun Yat-Sen UniversityCollaborator
- Sun Yat-Sen UniversitySponsor investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.